| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4261258 | Transplantation Proceedings | 2009 | 5 Pages |
Abstract
Our regimen of three consecutive autologous peripheral stem cell transplants with a reduced dose of melphalan at 100 mg/m2 given every 3 weeks was very well tolerated. The progression-free survival and overall survival are similar and can be compared favorably with the standard tandem myeloma regimens. Our data is intriguing, and further studies with larger numbers need to be performed to confirm these results.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
D. Berz, G.A. Colvin, E.M. McCormack, E.S. Winer, P. Karwan, L. Colvin, R. Rathore, L.G. Lum, G.J. Elfenbein, P.J. Quesenberry,